Skip to main content

AHP Subscribes to Incyte and Celera Databases in Search for Drug Targets


Why induce a financial headache by paying millions of dollars for two separate genetic databases when GenBank’s data is available from the government for free? Just ask American Home Products, maker of popular pain reliever Advil, which recently signed up for subscriptions to the databases offered by both Celera Genomics and Incyte Genomics.

“GenBank is derived from many sources and is inconsistent in quality,” Patrick Gage, president of Wyeth-Ayerst Research, the pharmaceutical research division of AHP, told BioInform.     

Gage said that AHP decided to subscribe to both since each of the commercial databases offers researchers unique insight into the genome as they mine for drug-target gold.

Celera’s databases contain the actual DNA sequence of a particular genome. So no matter how the genes are alternatively spliced in the production of different proteins, the database will contain the sequence. Incyte’s database holds cDNA clones, or DNA copies of the parts of the genome that are expressed, providing better clues into what proteins it will produce.         

Celera’s particular advantage, said Gage, lies in the software. A subscription to Celera’s database includes a bioinformatics package for viewing, browsing, and analyzing genomic information. 

“The amount of data is enormous,” said Gage. Celera’s database and software “provides us with an encyclopedia to go to instead of having to generate all that data ourselves.”

Gage said AHP would use its new database subscriptions to accelerate its search for new targets for small molecule drugs, particularlyproteins.

He would not say how much the Madison, NJ-based company paid for the access but said the fees were similar to what other organizations have paid.

Aaron J. Sender

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.